Yuhan Corporation, Sungkyunkwan University, and I'mNeuron Establish Central Nervous System Research Center

[Asia Economy Reporter Cho Hyun-ui] Yuhan Corporation announced on the 24th that it has signed a tripartite cooperation agreement with Sungkyunkwan University and I'mNeuron Bioscience for the 'Industry-Academia Convergence Brain Disease R&BD Ecosystem Construction Project.'

According to this agreement, Yuhan Corporation, Sungkyunkwan University, and I'mNeuron will promote ▲ the establishment of a CNS (Central Nervous System) Research Center ▲ joint research and new drug development cooperation ▲ securing CNS new drug projects ▲ and the establishment of a department in the field of basic brain science technology.

The CNS Research Center (tentative name) is planned to be established on a 7,000-pyeong scale within the Natural Science Campus of Sungkyunkwan University. Architectural design will begin in the second half of this year, followed by construction in 2021. Completion is targeted by the end of 2023.

This tripartite agreement is the first in Korea to realize a one-stop industry-academia cooperation platform for creating a brain disease research ecosystem involving a university, a bio venture, and a pharmaceutical company.

Through this cooperation, Yuhan Corporation plans to focus its capabilities on developing new drugs for brain diseases and expand CNS candidate substances with promising business potential.

Lee Jeong-hee, CEO of Yuhan Corporation, stated, "Through the brain disease R&D platform combining a pharmaceutical company, university, and venture for the first time in Korea, we will leap forward as a global company."